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Abstract: 
 The burden of neural degeneration is one that is becoming more steadfast in humans as we 
are beginning to live longer lives. Combating the entropy of being can, potentially, be accomplished 
using embryonic stem cells as they differentiate into neural stem cells via the exposure to certain 
mutagens like retinoic acid (RA), BMP2 antagonist noggin, and a variety of different tropic factors. 
Using these molecules in a precise manner can allow us to guide stem cells to the identity of our 
choosing, thus allowing us the opportunity to replace damaged brain tissues. The addition of RA, 
BDNF, and GDNF show to effectively increase dopamine production from progenitor cells, which 
has promising implications for patients suffering from Parkinson Disease. Huntington Disease also 
proves to be amendable to cell therapy as GABAergic neurons are efficiently regenerated in a rat 
striatum lesioned with quinolinic acid. Furthermore, multiple sclerosis benefits from the addition of 
stem cells as they secrete neuroprotective agents like CNTF that attempt to shield existing myelin 
from the attack of autoimmune antibodies. Stem cell research can be a fickle process that yields 
positive results less frequently than desired. However, we are beginning to know more about stem 
cells than ever before, and if we keep pushing the limits of our knowledge, the return will far exceed 
the investment. 
Introduction: 
 Stem cells are best characterized by their capacity to differentiate into multiple types of cell 
lineages. Different degrees of this ability exist: totipotentcy, pluripotency, and multipotentcy. The 
first of which has the highest potential to produce progeny from all cell lineages. Cells of this 
classification only exist a few days after the formation of a zygote. As the zygote replicates and 
forms a blastocyst, this ability is lost; the cells of the inner cell mass are now pluripotent and can give 
rise to all three germ layers[1]. These cells are now deemed embryonic stem cells (ESCs), and they are 
the focal point of cell therapy due to their differential plasticity.  
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 Stem cell research has exploded in the past couple of decades as the excitement regarding 
their potential continues to build. The optimism surrounding ESCs is predicated on their ability to 
serve as potential therapies for congenital and degenerative pathologies. The reputation of stem cells 
appears to be something of science fiction, however there appears to be a likely explanation for the 
presence of stem cells in the human body. It is hypothesized that the restorative ability of stem cells 
rests on their evolutionary upbringing. It seems probable that natural selection would favor 
individuals who possessed the capability to repair/replace damaged tissues from acquired lesions; 
thus, over time, this ability would become fixed in the human species[26]. All humans, young and old, 
have a certain number of adult stem cells (ASCs) spread throughout their body working 
constitutively with everyday functioning[2].  
 The supposition regarding the presence of stem cells dates more than a half a century prior 
to the verification of their existence. In the early 1920s, Alexander Maximow, a Russian 
embryologist, was puzzled by the idea of a single cell creating all the different types of cells found in 
the mammalian body. He envisioned that these cells must have some capacity to change or morph 
into other cell types, he referenced them as “polyblasts”[3].  Indeed, Maximow’s idea was based on 
sound logic, but he had no idea that he had just described the ESCs that would later become a 
medical sensation. Even with Maximow’s intriguing speculation regarding ESCs, it was not until 
1981 that the first ESC lines were characterized from mouse embryos[4]. Even then, it was not until 
1998 that the first derivation of human ESC lines were developed and subsequently documented[1,5].  
 Although ESCs are the highlight of cell therapy, there are two other broad classifications of 
stem cells. The first are the aforementioned ASCs which exists in all humans throughout their 
lifespan. The second type is the novel induced pluripotent stem cells (iPSCs). These are somatic cells 
that have been genetically altered to behave like ESCs with regards to pluripotency. The mechanism 
to accomplish this tells scientists a great deal about stem cells differentiation and will be discussed 
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later. iPSCs are an attempt to circumvent the ethical concerns surrounding ESCs. Other stem cells 
will be referenced; however, ESCs still show the most promise, thus this paper will emphasize these 
cells as they are the precursors to neural stem cells (NSCs). 
Potential Treatments using ESCs and their Stem Cell Progeny: 
 ESCs represent a section of cells from the inner cell mass that has unlimited differential 
potential. They are essentially immortal as they can divide an infinite amount of times if they are not 
shunted into certain cell lineages. But, even when differentiation occurs, there are many subsets of 
multipotent stem cells that can be produced. These subsets, like hematopoietic and mesenchymal to 
name a couple, have the potential to treat a large list of diseases. This list may include diabetes, 
osteoporosis, and kidney, lung, liver, heart, and some autoimmune diseases[6].  
 Perhaps the largest interest regarding ESCs is their ability to differentiate into NSCs. By 
traveling the neural route on the cell pedigree, the stem cells are now able to serve as a likely cure for 
many congenital and acquired neurological diseases. These would include: Parkinson, Huntington, 
and Alzheimer’s Disease, along with amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), 
spinal cord injury (SCI), and stroke[7]. An interesting finding from the research of NSCs is that the 
mechanisms of remedy seems to differ among certain pathologies. For example, treatment for 
Parkinson and Huntington Disease functioned best when the stem cells regenerated lost or 
degenerate neurons. Furthermore, patients suffering from MS showed the most improvement when 
the NSCs enriched the remaining neurons by the secretion of tropic factors[7-8]. As of now, scientists 
do not know why different conditions benefit better from different mechanisms of therapy. The 
best guess is that it has something to do with the stem cell differentiation in their respective niche, 
which highlights the paramount aspect regarding the attempt to harness their remedial power. 
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Stem Cell Differentiation: 
 An intuitive notion in utilizing stem cells for therapeutic purposes lies behind understanding 
the mechanisms of differentiation. Scientists are exploring two aspects of differentiation that 
supersede all others: the maintenance of pluripotency in ESCs and NSCs responses to different 
paracrine signals and transcription factors to specify neural subtype. The former is warranted if 
scientists are to continually grow ESCs that will then differentiate into NSCs, so this will be explored 
first.  
Maintaining ESCs for Pluripotency: 
 The ability to grow ESCs in culture is predicated on the prevention of spontaneous 
differentiation. There is an interplay between many intrinsic and extrinsic factors that control cell 
morphology. There are several transcriptional homeoproteins that control differentiation, but the 
most imperative is Leukemia Inhibiting Factor (LIF)[9]. This cytokine is released by adjacent cells and 
functions via juxtacrine interactions. Notably, the undifferentiated cells seem to be incapable of 
secreting this, thus requiring the presence of fibroblasts or differentiated cells with this capacity[9]. 
 The warrant of feeder layers, composed of cells that supply LIF, has been accomplished 
using mouse fibroblasts. This layer of nutrient-rich mouse cells has been effective at supplying LIF 
to keep the cells in an undifferentiated state, however it comes with threatening consequences[10]. If 
ESCs are to be commercialized, all potential malignancies must be eradicated. In the case of mouse 
feeder layers, the worry surrounding retroviruses should not be overlooked. To approach this 
concern, scientists have proposed using human feeder layers from infant foreskins, as they have 
shown to be effective at giving rise to fibroblast-like progeny that are capable of supplying LIF]10]. 
 Although LIF is necessary to prevent differentiation in most ESCs, it is not exclusionary to 
other transcriptional regulators. Scientists have shown that bone morphogenic protein-2 (BMP2) 
increases the efficacy of LIF via synergistic mechanisms. BMP2 works to activate inhibitor-of-
 Neurologic Stem Cells  6 
differentiation (Id) genes via the Smad signal propagation pathway[9]. Due to the fact that many 
signals and pathways contribute to differentiation, BMP2 blocks one of these pathways and 
indirectly increase the expression of signal transducer and activator of transcription-3 protein 
(STAT3), which is activated via LIF and its propagatory pathway[10-11]. 
 Previously, there was no known transcription factors that led to the maintenance of 
pluripotency without the help of LIF/STAT3 pathway. However, scientists have now discovered a 
protein that seems to control differentiation independent of LIF/STAT3[12-13]. After mutating the 
gp130 receptor that is the initiator of the STAT3 pathway, the addition of homeoprotein Nanog was 
observed to maintain pluripotency 60% better than LIF even in the presence of known 
differentiating ligands like retinoic acid (RA)[12]. Furthermore, this eliminates the need for feeder 
layers as this pathway is independent of LIF. Even though Nanog has shown to increase self-
renewal, the mechanism is not yet well understood. 
 There are still a large number of other ways to control transcription of genes and maintain 
pluripotency, but the aforementioned two (Nanog and LIF) seem to be the most inclusive. Oct-3/4 
are POU transcription factors that assist in maintaining an undifferentiated state, but the 
overexpression of this protein provokes differentiation to embryonic meso/ectoderm[14]. This is the 
epitome of the intricacies surrounding ESC differentiation and the balance of contributing factors. 
Furthermore, scientists have also reported the addition of telomerase can help the ESCs to maintain 
optimal potential. This enzyme protects cells from senescence since ESCs undergo massive 
replication that could compromise the integrity of their telomeres[15].  
 The knowledge with regard to the maintenance of pluripotency is novel and needs to be 
better understood. Progress is being made, however, as scientists are starting to maintain more lines 
of cultured ESCs than ever before[1]. But, ESCs provide no benefit to science if the power of 
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directed differentiation cannot be exploited, thus the realm of neural subtyping is next to be 
discussed. 
Differentiation into Neural Subtypes: 
 The maintenance of pluripotency serves only as a prerequisite to guided differentiation into 
other cells types. To be effective, scientists must control cell morphology into neuroectoderm and 
subsequently into specific subtypes of neurons and glial cells. It has been shown that the largest 
contributors to the development of neuroepithelia is the administration of RA and BMP2 
antagonist: noggin[11,16-17]. Schuldiner et. al effectively demonstrated that the exposure of ESCs to RA 
increased the expression of mature neuron marker neurofilament heavy chain protein (NF-H). This 
protein was found at a 25% increase in embryoid bodies treated with RA as opposed to the 
untreated control group. Furthermore, the same group found that ESCs treated with RA expressed 
dopamine receptor DRD1 and two serotonin receptors (5HT2A and 5HT5A) and tested positive for 
dopa-decarboxylase enzyme, a protein that is critical in the synthesis of both dopamine and 5HT[16].  
 Analogous to ESCs, NSCs display vulnerability to intrinsic and extrinsic factors, but their 
fate seems to be particularly dependent upon the time of exposure to different morphogens[18]. It 
was found that the exposure of neuroprogenitor cells (NPs) to fibroblast growth factor-8 (FGF8) at 
the beginning of development favors the production of midbrain-type dopaminergic neurons, 
whereas the deferred addition of the protein does not seem to influence the NPs in the same 
manner[19]. This highlights how timing has just as great an effect as the type of morphogen used. 
 Intuitively, the identity of the morphogen will prove to be significant also. In the developing 
fetus, rostral circuitries and connections seem to be more primitive than their more caudal 
counterparts[18]. If chemical guidance is stopped after the formation of NPs, almost all of the cells 
will turn into neurons and glial cells with more anterior properties[20]. The addition of RA was shown 
to effectively caudalize the cells by inducing the expression of certain Hox genes; additionally, RA 
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was shown to inhibit the formation of forebrain identities through the suppression of Otx and Bf-1 
operons[27]. However, in the unhindered brain, cells begin to secrete factors such as Wnt 
glycoproteins which effectively modify some existing entities into a more caudal identity[21]. 
Furthermore, it is suggested that forebrain tissues retain their primitive identity by resisting Wnt 
signaling through soluble antagonists released by adjacent entities[22]. The discrimination between 
rostral and caudal tissues is important as they carry different properties[18]. It may seem curious to 
suggest that neurons of the same classification (i.e. dopaminergic) can be strikingly different solely 
on the basis of their spatial positioning in the brain; however, it is not disputed that dopaminergic 
neurons have a unique role in the substantia nigra (projection area) when compared to the 
somatosensory cortex (association area). Against the best attempts to recapitulate the native niches 
of NSCs, scientists have only been able to successfully subtype small amounts of neurons and glial 
cells. This is a testament to the multifaceted nature of the human brain. The delicate balance of 
neuron morphology is two-fold: it depends on the morphogen identity as well as the timing of ligand 
binding. As such, this is tough to reproduce in vitro.  
 Neurons in the brain are subject to their respective signaling pathways and transcription 
factors. Generally, they all emulate the same basic outline as any other somatic cell: ligand binding, 
tyrosine kinase activation, scaffolding, and then propagation which ultimately leads to the expression 
of some proteins that give the neuron its subtype distinctiveness. For the purposes of this paper as 
an overview, it suffices to appreciate that each subtype expresses a unique protein pattern at very 
specific times that ultimately guides it to synthesize its respective neurotransmitter. The non-motor 
CNS neurons are astonishingly complex thus most results are rather cumbersome. However, motor 
neurons in the CNS and PNS seem to be better understood. 
 Although it has been tough to recreate the conditions of the brain for specific subtypes. 
Motor neurons have perhaps made the greatest progress regarding growth and guided development, 
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as the attempts to recreate in vivo conditions have been more successful. It has been found that Sonic 
the Hedgehog (Shh) signaling protein plays a large role in the development of motor neurons from 
caudal prerequisites[22-23]. Specifically, motor neuron progenitors (MNPs) are regulated by Shh via 
homeodomain (hD) and basic helix-loop-helix (bHLH) transcription factors[23]. It has been shown 
that the continued addition of exogenous Shh produced high levels of two hD proteins, Pax6 and 
Nkx6.1, and Olig2, a bHLH peptide[17, 24]. The high concentrations of these regulators drives the cell 
to become a motor neuron and removes the possibility of it differentiating into other types of neural 
progeny[25]. The aforesaid pathway is not demonstrative of the entire process, but it illuminates the 
key characters at play. Nevertheless, the progress that has been made with regards to motor neuron 
development sheds light on potential to eradicate pathologies that involve the loss of these neurons. 
 The complexities surrounding neural circuitries renders any meaningful progress infrequent. 
Currently, scientists have ideas of transcription factors and signaling pathways that are important to 
gross arrays of neurons, but neural subtyping is very specific and must be better understood to be a 
real asset to potential therapies. Regardless of the lack of knowledge in some areas, there are a 
variety of cell therapies that have been successful on many different pathologies, and these will now 
be investigated. 
Neurologic Pathologies Potentially Amendable to Cell-Based Therapies: 
 In the previous section, the differentiation of ESCs was explored along with the guidance 
into fore/hindbrain and motor classifications. Here, the highlights of cell-based therapy will be 
exploited to show there is a great deal of potential in this field of science. Specifically, Parkinson 
Disease, Huntington Disease, and multiple sclerosis will be presented in depth. 
Therapy for Parkinson Disease: 
 Parkinson Disease (PD)  is categorized as the loss of dopaminergic (DA) neurons from the 
substantia nigra and other projection areas in the brain. Patients with this disease present with motor 
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difficulties and also exhibit problems with speech and fatigue.  To combat this neurodegenerative 
disease, scientists have questioned whether the transfection of DA progenitors into key areas could 
show any remedial results.  
 The success of any cell-based therapy relies on the ability to grow a large quantity of cells in 
vitro so they may be transfected into human (or mouse) patients. This is where the aforementioned 
knowledge regarding differentiation and survivorship becomes imperative to the future of stem cell 
endeavors. Morizane et al. showed that large scale production of DA neurons is possible when ESCs 
are grown with PA6 feeder layers. It was discovered that these stromal cells secreted soluble factors 
such as glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor 
(BDNF), dibutyryl cyclic AMP (dbcAMP) and RA-analog ascorbic acid (AA), all of which have been 
found to assist cells in the production of dopamine[28]. A large portion of the cells grown tested 
positive for tyrosine hydroxylase immunoreactivity, which is a key enzyme in the pathway that 
catalyzes the formation of dopamine; this would indicative of DA progenitors. Furthermore, another 
study has success growing vast amounts of DA neurons in vitro for transfection. In this study, it was 
found that BDNF and transforming growth factor (TFG) – α were the major players that induced 
higher levels of dopamine production[29]. The exact influence of these factors on dopamine 
production has yet to be fully classified and reported, but what is known is that the above 
components have an effect in pushing NSCs to form DA neurons. 
 Once large amounts of healthy progenitors have been identified, they are ready for 
transplantation. Zhang et al. performed an experiment were the injectable neurons were 
fluorescently labeled so they could be detected after transfection. The researchers showed that after 
in situ injection into the brain, the progenitor cells actually migrated very effectively and incorporated 
into many areas of the brain including the hippocampus and the striatum[30]. The state of stem cell 
development during transfection is very key: the neurons need to be near the median of a nascent 
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NSC and fully differentiated DA state. This allows to adherence to certain lineages depending on 
their respective niche[30]. Terminally differentiated cells do not perform well under in vivo conditions 
not suitable to their exact subtype. It seems successful transfection with completely mature neurons 
is more difficult to obtain as their reduced malleability has large repercussions on their viability.  
 One of the most successful trails on PD was performed on rats that have acquired lesions 
that allowed them to serve as a model of patients with PD. In this experiment, Björklund et al. 
displayed that the transplantation of progenitor cells fully differentiated into DA neurons in the rat 
model. After time, the transfected neurons tested positive for TH-immunoreactivity and proliferated 
into healthy midbrain-like DA cells. The cells also showed to migrate heavily into many areas of the 
brain and respond to cues from endogenous NSCs which makes this a promising study for future 
research. The authors also reported that the rats showed vast improvements in motor competence as 
well as a large reduction in extrapyramidal effects and asymmetries, thus reducing the effect of PD in 
rats[31]. 
Therapy for Huntington’s Disease: 
 Huntington’s Disease (HD) is a neurodegenerative condition in with the brain exhibits loss 
of crucial medium-spiny, GABAergic neurons in the striatum, a deep tissue layer in the midbrain[32]. 
It has been found that the disease is brought on by an autosomal dominant mutation in the 
huntingtin (htt) or IT15 gene which is located on chromosome 4[33]. Although scientists have been 
able to locate the exact location of the mutation, the method of action of the alteration is widely 
unknown thus hampering effective treatments. However, cell therapy does provide some promising 
upside for patients with this terminal disease. 
 In order to study HD, or any pathology, scientists must be able to recreate the diseased 
condition in a lab setting. This was particularly challenging for researchers looking to induce 
Huntington-like lesions in the brains of rats. After careful consideration and many biochemical test, 
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it was found that injection with N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid 
(QA) most closely provides a neurochemical benchmark that seems to emulate conditions of HD[34]. 
The NMDA receptor works to bind very excitatory neurotransmitters like glutamate, and thus act to 
oppose inhibitory GABA molecules in the brain. The continued antagonism of these GABAergic 
neurons eventually leads to atrophy with closely mimics the loss of these neurons in HD. 
Furthermore, Beal et al. solidified the use of QA showing that it also led to increases in aspiny 
neurons like somatostatin and neuropeptide Y which are also commonly seen in HD patients[34]. 
 As displayed with the DA neurons in PD, scientists now know they can grow large amounts 
of ESCs on feeder layers. The next step with regard to treatment of HD is that of administration. As 
aforementioned, the tissues affected by this disease are deep within the brain, and this renders 
patients vulnerable to collateral trauma if probing instruments damaged viable tissues on their way to 
the striatum. Promisingly, it has been found that NSCs can actually migrate relatively vast distances 
to areas of lesion and integrate into the affected tissues[39]. Specifically, this seems to eliminate the 
need for invasive techniques that could be more malignant than beneficial. 
 Due to the curiosity regarding the mechanism of HD, many researchers have attempted to 
find a therapy for the condition even if they were not precisely certain on the course of action. 
Promisingly, it was found that NSCs that have not been terminally differentiated actually exhibited 
GABAergic phenotypes when xenografted into the striatum[35-37]. Specifically, Aubry et al. found that 
the progression of NSCs into striatal progenitors was marked by the expression of GSH2 and DLX2 
genes, along with the detection of DARPP32 protein which is indicative of terminally differentiated 
neurons[35]. Furthermore, Song et al. found that ESCs grown on PA6 feeder layers prompted 
positive results when transfected into rats with unilateral QA lesions; the rats showed vast behavioral 
and histological improvements in as little as one week[36]. Similarly, McBride et al. found the same 
positive result with regard to NSCs integration and differentiation into GABAergic neurons. 
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However, here they report that cytokine ciliary neurotropic factor (CNTF) seemed to speed the 
recovery processes in rats with QA lesions; however, it was also shown that neurons in the CNTF 
treatment group actually responded less to cytokine and chemotaxic cues[37]. This hinders them from 
migrating to areas of lesion, thus CNTF is hypothesized to have a nonselective desensitization effect 
on neurons. 
 A notable difference between PD and HD is that the latter has a genetic origin. This brings 
different treatment options as scientist can attempt to preemptively combat the disease depending 
upon whether someone is at risk due to family history. Interestingly, in a study using rats with 
induced QA lesions, Ryu et al. found that cell therapy was extremely effective in reversing the effects 
of neuronal loss and degradation of GABAergic neurons if the NSCs were administered proactively 
as opposed to subsequent to lesioning. They, then, hypothesized that the cause of this was the 
neuroprotective release of BDNF from the exogenous NSCs. BDNF was shown to have a 
protective effect on cells against mutagens in vitro and secretion of this agent was very high following 
administration of NSCs, leading the researchers to this conclusion[38]. With an onset in the mid 20s, 
HD could be effectively reduced or eradicated with proactive treatment. 
Therapy for Multiple Sclerosis 
 Multiple sclerosis (MS) is an autoimmune disease in which antibodies are made against 
certain components of the myelin sheath that wraps neurons. As a result, episodes of vicious 
demyelination characterize the life of patients with this disease. Treatments are limited to 
plasmapheresis and symptom alleviation rather than halting the progression of the disease. Cell 
therapy gives a promising insight as to the future of disease prevention and amelioration. 
 To recreate the neuroenvironment, scientists induce experimental autoimmune 
encephalomyelitis (EAE), which is an inflammatory and demyelinating disease of the CNS that 
closely imitates what is seen in the CNS plagued with MS[40]. Subsequent to lesioning, the scientists 
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transfected NSCs intravenously and monitored their migrations. Most (~90%) showed expressions 
of key proteins like CD44 and very late antigen (VLA) -4 while also lacking a class of common 
glycoproteins and selectins; the combination of present and absent proteins appears to be consistent 
with molecules that can pass the blood brain barrier (BBB)[40]. Later, they found injected cells 
sufficiently migrated to areas of destruction and began secreting immunomodulatory actors such as 
CNTF. Furthermore, it was discovered that CNTF’s immunosuppressive effect functions by 
inhibiting the transcription of the proinflammatory cytokine TNF- α, and it was also shown to 
increase the efficacy of oligodendrocyte progenitors (O-2A)[40]. As a result, the scientists of this study 
suggest intravenous administration of NSCs may allow passage of the BBB and effective 
remyelination without the need for invasive procedures.  
 In another study of MS, EAE rats were injected with NSCs and the differentiation of the 
stem cells to O-2A was monitored. This was done by observing expression of genes through their 
protein product. An A2B5+PSA-NCAM- phenotype was needed to confirm that the cells were 
indeed O-2A cells and not cell adhesion progenitors that show similar protein patterns[41]. Here, 
survivorship was not recorded due to the fact that all mice were euthanized and brain tissues were 
harvested. Upon examination, it was found that O-2A cells effectively migrated to areas and began 
to rebuild axonal myelination[41]. A point of contention with the aforementioned study could regard 
whether or not perceived O-2A cells were of exogenous origin. To combat this doubt, another team 
modified the O-2A genome to express bacterial β-galactosidase; this created unique 
oligodendrocytes that could be distinguished from the indigenous cell population. Promisingly, the 
researchers found a large population of β-galactosidase positive O-2A cells integrating into the 
neural circuitries in areas of vast demyelination[42]. 
 Previously, it was mentioned that stem cell therapies can differ in their means of remedy. It 
has been suggested that stem cell therapy is not a one-size-fits-all, but rather an intricate balance of 
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unique rehabilitating factors. Whereas most of cell therapy is grounded in the replacement of 
degenerate cells, Lee et al. found that, in some conditions, the nourishment and biotic assistance 
from exogenous NSCs actually proves to be a better therapy than cell replacement[43]. In the case of 
MS, the tropic enrichment of existing myelinated axons and oligodendrocytes has proved to be a 
superior treatment than the regeneration of the cells themselves[7-8]. Furthermore, ALS seems to 
benefit from similar treatments showing widespread remyelination of axon from injected stem 
cells[44-45]. 
 In a rare clinical trial of NSCs on MS and ALS, the researchers found that 3 out of the 4 
patients exhibited progression in MS symptom relief following injections; although, only one patient 
noted permanent progression and remyelination[46]. This elucidates the ambiguous nature of NSCs 
treatment. The very fact that improvement was shown is encouraging; however, continued 
improvement is warranted if cell therapy is to become commonplace and a pragmatic treatment for 
congenital and degenerative diseases. 
Challenges Facing Cell-Based Therapy: 
 Aside from the fact that scientists do not know enough about stem cells, there are still a 
number of concerns regarding the effectiveness and safety of cell therapy. The implications of these 
concerns have caused hesitation from organizations like the FDA and other agencies that are 
imperative to the funding of stem cell endeavors. In fact, in 2009, the FDA put a complete halt on 
clinical trials of ESCs as the threat posed by certain problems seemed too great to continue[47]. They 
have since reinitiated clinical trials, however lots of individuals in the scientific community remain 
apprehensive. 
 Perhaps the most imposing hazard with regards to ESCs is their tendency to over-proliferate 
in their new niche, consequently resulting in teratomas[48]. The drive to replicate is an innate feature 
of ESCs, as just a few cells are to eventually become an entire organism. Thus, scientists must find a 
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way to suppress this natural inclination by further characterizing mechanisms involved and finding a 
way to antagonize this primordial characteristic. Perhaps, ASCs would be a more suitable alternative 
as they no longer have the intrinsic drive to multiply to rapidly. 
 As with any transplant, the risk regarding immunological rejection is always high. This has 
significantly impeded the process of cell therapy as the quest to find a compatible donor is no small 
feat. This has pushed scientists to overcome this concern with the invention of iPSCs[47]. This 
characterization of iPSCs is extremely novice and predicated on the researcher’s ability to revert a 
somatic cell back to its embryonic origin through the addition of certain transcription factors; 
however, work done in this field is novel and results are very unconvincing as of yet. It may seem 
that the introduction of iPSCs is invulnerable to complications, yet these autologous stem cells still 
carry the same genetic predispositions as the degenerate cells of which they are trying to replace[7]. 
Furthermore, the process of reversion in iPSCs is not well understood and thus carries the potential 
to reactivate oncogenes that could lead to the formation of teratomas[49]. 
 It is important to appreciate that scientific research cannot exist independently of those 
organizations that are able and willing to fund these undertakings. Moreover, the government has a 
large impact of the progress of science through the allocation of funds. Seeing as the President and 
congress are not permanent positions, elected officials move in and out of those seats carrying their 
personal view on stem cell research with them as they come and go. As such, this has a profound 
impact on research ability depending on the current views of those in office. The ethical and moral 
obligations of politicians is a large factor in maintaining public image, thus they are normally 
contempt to deviate from their promises. In 2001, President Bush signed an executive order banning 
the use of federal funding for stem cells research, an order than President Obama overturned in 
2009[50]. This one example is illustrious of the haphazard nature of stem cell funding, and since 
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research depends on these politicians, it highlights exactly why research efforts can be rather 
precarious. 
Conclusion: 
 ESCs show the greatest promise for the treatment of neurologic diseases as their ability to 
differentiate into NSCs is key to the regeneration of functional cerebral capacities. As discussed, 
these cells exhibit the ability to amend severe degenerative and congenital pathologies of which we 
only have treatments for the symptoms. Great progress is being made on the understandings of 
pluripotency and the mechanisms of differentiation; while harnessing this knowledge, it is possible 
to divert stem cells from their evolutionary fate and redirect them to the identity of our preference. 
In the coming decades, it is possible for the likes of PD, HD, MS, ALS and others to be obsolete or 
as rudimentary as the common cold.  
 Moving forward, we must better understand the local niche as to properly recapitulate 
conditions in vitro. We must create better methods of transfection as to minimize the potential of 
collateral trauma and transplant rejection. We must identify potential oncogenes, silence them, and 
prevent their reactivation in iPSCs and transplanted ESCs. With technologies improving every year, 
it is not outrageous to suggest that these challenges can be overcome sooner rather than later. If 
scientists can accomplish these seemingly insurmountable feats, the human race will have taken a 
giant leap in the direction of improving the quality of life for hundreds of thousands of people all 
over the world. The implications of this paints a vivid picture of what could be; the miraculous 
restorative ability of stem cells remains virtually untapped. This fact keeps us optimistic, it keeps us 
going, and it keeps us hungry to know more. 
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